TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04772677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BEAM Mental Health and Parenting Program
Description: The BEAM program is a novel mobile app-based therapeutic intervention that incorporates key parenting concepts and Unified Protocol (UP) therapy modules with clinician-facilitated peer social support and connection. The primary aim of the program is to improve symptoms of depression and promote a positive parent-child relationship. There are three main components of the program: 1) the UP content, which will target maternal mental health symptomology, 2) the parenting skills training content, which is designed to correspond to the UP modules and promote maternal responsivity to children's emotions, and 3) a closed online community forum to encourage social support and connection between participants of the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BEAM Mental Health and Parenting Program
Description: The BEAM program is a novel mobile app-based therapeutic intervention that incorporates key parenting concepts and Unified Protocol (UP) therapy modules with clinician-facilitated peer social support and connection. The primary aim of the program is to improve symptoms of depression and promote a positive parent-child relationship. There are three main components of the program: 1) the UP content, which will target maternal mental health symptomology, 2) the parenting skills training content, which is designed to correspond to the UP modules and promote maternal responsivity to children's emotions, and 3) a closed online community forum to encourage social support and connection between participants of the program.
Study: NCT05866107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: self-monitoring of weight using smart body fat scale with high-precision weighing chip (Huawei Scale 2pro), a mobile phone app (Huawei Health), dietary management, and exercise management.
Description: Participants will use a mobile phone app (Huawei Health) to collect data on sleep log, daily activities and calorie consumption. The smart body fat scale with high-precision weighing chip (Huawei Scale 2pro) will be used to collect heart rate, weight, BMI, body type, basal metabolic rate, fat rate, fat free body weight, skeletal muscle mass, bone salt content, visceral fat grade, body water (%), body protein rate and body composition, and all data will be uploaded to the app. Participants could also record their daily dietary intake (for calculation of calorie intake) in the health app; psychiatrists evaluate the patient's condition and conduct laboratory tests; nutrition instructors conduct dietary education and formulate individualized energy-limited balanced diet prescriptions; exercise instructors conduct behavioral ways and sports education, and individualized exercise prescriptions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: self-monitoring of weight using smart body fat scale with high-precision weighing chip (Huawei Scale 2pro), a mobile phone app (Huawei Health), dietary management, and exercise management.
Description: Participants will use a mobile phone app (Huawei Health) to collect data on sleep log, daily activities and calorie consumption. The smart body fat scale with high-precision weighing chip (Huawei Scale 2pro) will be used to collect heart rate, weight, BMI, body type, basal metabolic rate, fat rate, fat free body weight, skeletal muscle mass, bone salt content, visceral fat grade, body water (%), body protein rate and body composition, and all data will be uploaded to the app. Participants could also record their daily dietary intake (for calculation of calorie intake) in the health app; psychiatrists evaluate the patient's condition and conduct laboratory tests; nutrition instructors conduct dietary education and formulate individualized energy-limited balanced diet prescriptions; exercise instructors conduct behavioral ways and sports education, and individualized exercise prescriptions.
Study: NCT05351580

Intervention type: DEVICE
Intervention: DiSCERN
Description: Smart watch Monitoring

Intervention type: DEVICE
Intervention: DiSCERN
Description: Smart watch Monitoring
Study: NCT04904224

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Panintestinal video capsule endoscopy
Description: Performing a video capsule endoscopy using the Pill Cam Crohn's capsule from Medtronic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Performing a standard colonoscopy using the colonoscope available in the study center
Study: NCT06218472

Intervention type: OTHER
Intervention: Day Hospital Treatment
Description: Scheduling of 12 half-day sessions per week, alternating between sessions with only the patients or involving the entire family. Close medical monitoring and multidisciplinary interventions during sessions (pediatrician, psychiatrist, dietitian, recovered former patients...).

Intervention type: OTHER
Intervention: Multidisciplinary follow-up as usual within the service
Description: Multidisciplinary follow-up as usual within the service

Intervention type: OTHER
Intervention: Conduct semi-structured qualitative interviews
Description: Conduct semi-structured qualitative interviews
Study: NCT05300945

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC after gastrectomy with D2 local lymph node dissection.
Study: NCT05667324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: A single injection into the pterygopalatine fossa bilaterally of 0.5% ropivacaine at a dose of 20 mg (each side)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Plus 4 mg dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Plus 4 mg dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A single injection into the pterygopalatine fossa bilaterally of a balanced crystalloid intravenous solution (4 ml of normal saline)
Study: NCT06364995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volleyball
Description: Volleyball Specialised Physical Education Intervention is a step-by-step approach to teaching the intervention. Each lesson was conducted as a Warm-up (10 minutes), Basic contents of the PE lesson (25 minutes), and Cool-down (5 minutes). From the learning of basic skills in the first session to the final Combination Practice underhand service, receive, service, pass, spiking, and block, from the simple to the difficult, the intensity of the training is from weak to strong, Allowing participants to build upon a solid foundation toward mastering intricate volleyball maneuvers. Intensity modulation is key to this intervention; training intensity evolves from moderate to vigorous, aligning with the increasing complexity of skills and the physical demand required to execute them proficiently. The curriculum is thoughtfully designed to transition from basic skill execution to complex gameplay, with each lesson introducing new skills or refining existing ones.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Education
Description: Participants participating in the control group will attend traditional physical education classes following the established physical education syllabus. Participants in the control group will attend four 40-minute classes per week over ten weeks. Each session will consist of a warm-up (10 minutes), the basics of PE (25 minutes), and a cool-down (5 minutes). The duration and intensity of the experimental and control groups were the same, which allowed for a better comparison.
Study: NCT06314464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Praxis
Description: Praxis' gaze stabilization exercises are delivered via the tablet-based VestAid software that uses the tablet camera to automatically assess compliance in the conduct of vestibulo-ocular reflex exercises. The smooth pursuit, saccade, agility, and dual tasking exercises are delivered in the form of military-themed mixed reality games using the HTC Vive Focus 3 headset.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised cardiovascular exercise
Description: The supervised cardiovascular exercise does not incorporate gaze stabilization exercises (vestibulo-ocular reflex exercises) or smooth pursuit, saccade, agility, and dual tasking exercises.
Study: NCT05777733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-acetylcystine
Description: Single daily oral administration of N_acetylcystein on dose 10mg /kg/day
Study: NCT05635890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cawthorne Cooksey exercise protocol
Description: Cawthorne Cooksey exercise protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional vestibular rehabilitation
Description: conventional vestibular rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional vestibular rehabilitation
Description: conventional vestibular rehabilitation
Study: NCT05774340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05286060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-188E, GX-I7, Pembrolizumab
Description: Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 1200㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa Drug 3: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-188E, Pembrolizumab
Description: Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-188E, GX-I7, Pembrolizumab
Description: Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 360㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa Drug 3: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-188E, GX-I7
Description: Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 360㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa
Study: NCT05430269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faecal bacteriotherapy (FBT)
Description: Enema of 350 ml of standardised mixed transplantate prepared from faeces of 7 healthy donors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard-of-care protocolised treatment of postantibiotic diarhea
Description: standard-of-care protocolised treatment of postantibiotic diarhea
Study: NCT05150548

Intervention type: OTHER
Intervention: No Intervention
Description: Not applicable, non-interventional study
Study: NCT05818865

Intervention type: DEVICE
Group type: OTHER
Intervention: CLG
Description: The development of an innovative device (CLG) consisting of an aqueous gel based on hyaluronic acid and commercially available (Belotero) able to be loaded and to release chemokine CXCL12 recreating a kind of fake niche able to attract immune cells- and CTCs-CXCR4+. The added value is the ability to attract and trap cells capable of leaking out and potentially with a higher metastatic capacity.
Study: NCT05032950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam administered as a single dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir + Midazolam
Description: PF-07321332/ritonavir:~Administered orally every 12 hours for a total of 9 doses on Days 1-5~Midazolam:~Administered orally as a single dose on Day 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir + Midazolam
Description: Ritonavir:~Administered orally every 12 hours for a total of 9 doses on Day1-5.~Midazolam:~Administered orally as a single dose on Day 5
Study: NCT06287879

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Dry eye examination
Description: 1. Lacrimal river height~2. tear break-up time~3. tear-film lipid layer thickness~4. meibomian glands two-dimensional digital infrared images

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dry eye examination
Description: 1. Lacrimal river height~2. tear break-up time~3. tear-film lipid layer thickness~4. meibomian glands two-dimensional digital infrared images
Study: NCT05764967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Dye Taping
Description: The augmented low-Dye technique, involves applying a device consisting of a spur and mini-stirrups to the foot and then adding reverse sixes and calcaneal slings to an anchor on the distal one-third of the leg. A rigid 38-mm sports tape with zinc oxide adhesive is used for all of the taping procedures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Temporary Felt Insoles
Description: A temporary orthosis is fabricated from 7-mm orthopedic felt.The subject stands on his or her template while the TTR pointer is attached to the medial tibial plateau of the leg using a Velcro strap. An outline of the position of the device on the tibial plateau is drawn onto the skin with an indelible ink pen to allow for accurate relocation between all trials. TTR is measured in relaxed calcaneal stance while the subject wearing shoes. Measurements are recorded onto a data-collection sheet. Each measurement performes twice. The subject are given orthosis inserted into the shoe. All shoes are visually assessed to ensure that they will not induce pronation or internal rotation.
Study: NCT06542146

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: The Mediterranean diet is consisting of fruits, vegetables , legumes, whole grains, nuts, and olive oil as the main source ofdietary fat

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual diet
Description: Usual diet including routine diet we already eat
Study: NCT04785365

Intervention type: OTHER
Group type: OTHER
Intervention: Biological: ATL001
Description: No investigational product will be administered

Intervention type: OTHER
Group type: OTHER
Intervention: Biological: ATL001
Description: No investigational product will be administered
Study: NCT06037668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BVR-100
Description: Experimental self-guided VR intervention for the treatment of SAD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BES-100
Description: Active at-home VR intervention comparator
Study: NCT06538285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0.50 mg/kg IM will be administered during the first dosing visit, and either 0.50 mg/kg IM or 0.75 mg/kg IM will be administered at the two subsequent dosing visits, depending on the participant's toleration of prior ketamine dose(s). All ketamine dosing visits will be facilitated by a licensed study therapist and clinician (i.e., NP or MD).
Study: NCT06591377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 MG
Description: The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 MG
Description: The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 75mg
Description: The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 75mg
Description: The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
Study: NCT06617429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102
Description: antisense oligonucleotide

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: GTX-102
Description: antisense oligonucleotide
Study: NCT06538285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychotherapy will consist of three 1-hour preparatory talk therapy sessions over the 14 days preceding the first ketamine dosing visit, a 1-hour integration talk therapy session within 1-3 days following each ketamine dosing visit, and a final 1-hour integration talk therapy session about 1 week following the last ketamine visit. All talk therapy visits will be conducted by a licensed study therapist.
Study: NCT06617429

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-LP
Description: Small needle prick on the lower back at the location where the LP injection is normally made
Study: NCT06540079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solia CSP S lead
Description: The Solia CSP S pacing lead will be implanted in the LBBA for patients who meet all inclusion/exclusion criteria and give written informed consent.
Study: NCT05245643

Intervention type: DEVICE
Group type: OTHER
Intervention: Abbott Infinity Deep Brain Stimulation System
Description: DBS is robot-assisted, with 3D intraoperative imaging control, under general anesthesia. Target is defined thanks to preoperative dedicated MRI with 2 independent experts' assessment.
Study: NCT04770883

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet based cognitive behavioral therapy.
Description: Patients will receive iCBT for 10 weeks, divided into five successive steps. The iCBT will be guided by online therapists and emphasizes acceptance of symptoms through exposure training. Patients have to report that they have worked through a treatment step to get access to the next. Patients will be encouraged to work through steps 1-4 during the first half of the treatment and to spend the latter half on step 5, in which exposure exercises will be introduced. The treatment aims to break the vicious cycle between avoidance behavior, symptom severity and functional impairment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet based cognitive behavioral therapy.
Description: Patients will receive iCBT for 10 weeks, divided into five successive steps. The iCBT will be guided by online therapists and emphasizes acceptance of symptoms through exposure training. Patients have to report that they have worked through a treatment step to get access to the next. Patients will be encouraged to work through steps 1-4 during the first half of the treatment and to spend the latter half on step 5, in which exposure exercises will be introduced. The treatment aims to break the vicious cycle between avoidance behavior, symptom severity and functional impairment.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAP diet therapy
Description: Patients will receive 10 weeks of standardized treatment with low FODMAP diet consisting of 3 stages: FODMAP restriction; FODMAP reintroduction and FODMAP personalization. These stages will be covered in at least three appointments by primary care dieticians in Region Örebro County.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet therapy
Description: Patients will receive 10 weeks of standardized treatment with low FODMAP diet consisting of 3 stages: FODMAP restriction; FODMAP reintroduction and FODMAP personalization. These stages will be covered in at least three appointments by primary care dieticians in Region Örebro County.
Study: NCT05900206

Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab deruxtecan
Description: Experimental drug. Provided in 100mg vials. IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Experimental drug. Provided in 100mg vials. IV infusion.

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: Active comparator. IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Active comparator. IV infusion.

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Active comparator. IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Active comparator. IV infusion.
Study: NCT05224544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device
Description: The test product is a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: The comparator is a urinary catheter for bladder drainage through the urethra.
Study: NCT05900206

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Active comparator. IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Active comparator. IV infusion.

Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab
Description: Active comparator. IV infusion.
Study: NCT05079360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sabizabulin
Description: 32mg each day by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator
Description: Subjects in the Control Treatment Group will receive an ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site until disease progression is observed and confirmed by BICR. The investigator decision of which comparator treatment will be used will be made prior to randomization.